What TB-500 is
TB-500 is commonly described as a synthetic fragment related to thymosin beta-4 biology, with claims centered on cell migration and repair signaling.
TB-500 is grouped under Fitness + Recovery on PeptideFactCheck because it is marketed in recovery circles as a soft-tissue and mobility peptide, often beside BPC-157.
The useful starting point is to separate the molecule itself from the internet story around it. It gets sold online as the movement and recovery partner to BPC-157.
Why people keep looking it up
People talk about TB-500 for mobility, injury recovery, flexibility, and soft-tissue healing.
The claim comes from thymosin beta-4 biology around cell migration and repair signaling, but TB-500 is usually a fragment-related product claim.
TB-500 tends to stay in the conversation because it touches a familiar public theme: actin binding, repair signaling, and cell migration. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Direct human evidence for broad recovery claims is weak. Much of the story is borrowed from adjacent thymosin beta-4 research.
Human evidence for the common recovery claims is sparse and does not match the certainty of online marketing.
Thymosin beta-4 biology has preclinical and mechanistic literature, but TB-500 product claims are often extrapolated from adjacent evidence.
Why this page carries the current tier: Internet-popular with weak direct clinical support for performance and recovery claims.
The current seed trail for TB-500 is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.
Safety, limits, and regulatory context
Identity, purity, immune response, and claim inflation are major unknowns for non-approved research products.
No FDA-approved TB-500 drug product is listed in this V1 source trail. Verify current FDA bulk-substance status before making compounding-specific claims.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for TB-500. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for TB-500 is CID 62707662. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 62707662
- Formula
- C38H68N10O14
- Molecular weight
- 889.0
- InChIKey
- ADKDNDYYIZUVCZ-ZQNQAVPYSA-N
Matched synonyms include TB500, 885340-08-9, UNII-QHK6Z47GTG, TB-500, QHK6Z47GTG, (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid, TB 500, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for TB-500 returns 1 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for TB-500 returns 114 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.